Abstract：
UNASSIGNED: Female sexual interest and arousal disorder (FSIAD) is the most prevalent female sexual dysfunction in the postmenopause.
UNASSIGNED: The aim of this review is to provide a summary of the currently available evidence on the use of testosterone in the treatment of FSIAD in postmenopausal women.
UNASSIGNED: A narrative review on the topic was performed. Only randomized controlled trials (RCTs) and systematic reviews and meta-analysis were considered. 123 articles were screened, 105 of them assessed for eligibility, and finally 9 were included in qualitative synthesis following the PRISMA declaration.
UNASSIGNED: Current evidence recommends, with moderate therapeutic benefit, the use of systemic transdermal testosterone within the premenopausal physiological range in postmenopausal women with Hypoactive Sexual Desire Disorder (HSDD), the previous entity for low desire dysfunction, not primarily related to modifiable factors or comorbidities such as relationship or mental health problems. The available evidence is based on studies with heterogeneity on their design (different testosterone doses, routes of administration, testosterone use in combination and alone, sexual instruments of measurement). There is no data indicating severe short-term adverse effects, although long-term safety data is lacking.
UNASSIGNED: Despite having testosterone as a valuable tool, therapeutic strategies are lacking in the pharmacological field of HSDD/FSIAD. Neuroimaging studies could provide valuable information regarding the sexual desire substrate and suggest the potential application of already approved drugs for women with a good safety profile. The use of validated instruments for HSDD in postmenopausal women, considering the level of distress, is necessary to be able to draw robust conclusions on the evaluated treatments.
UNASSIGNED: The aim of this review is to provide a summary of the currently available evidence on the use of testosterone in the treatment of FSIAD in postmenopausal women.
UNASSIGNED: A narrative review on the topic was performed. Only randomized controlled trials (RCTs) and systematic reviews and meta-analysis were considered. 123 articles were screened, 105 of them assessed for eligibility, and finally 9 were included in qualitative synthesis following the PRISMA declaration.
UNASSIGNED: Current evidence recommends, with moderate therapeutic benefit, the use of systemic transdermal testosterone within the premenopausal physiological range in postmenopausal women with Hypoactive Sexual Desire Disorder (HSDD), the previous entity for low desire dysfunction, not primarily related to modifiable factors or comorbidities such as relationship or mental health problems. The available evidence is based on studies with heterogeneity on their design (different testosterone doses, routes of administration, testosterone use in combination and alone, sexual instruments of measurement). There is no data indicating severe short-term adverse effects, although long-term safety data is lacking.
UNASSIGNED: Despite having testosterone as a valuable tool, therapeutic strategies are lacking in the pharmacological field of HSDD/FSIAD. Neuroimaging studies could provide valuable information regarding the sexual desire substrate and suggest the potential application of already approved drugs for women with a good safety profile. The use of validated instruments for HSDD in postmenopausal women, considering the level of distress, is necessary to be able to draw robust conclusions on the evaluated treatments.
摘要：
■女性性兴趣和唤起障碍（FSIAD）是绝经后最常见的女性性功能障碍。
■本综述的目的是总结目前在绝经后妇女中使用睾酮治疗FSIAD的现有证据。
■对该主题进行了叙述性审查。仅考虑随机对照试验（RCTs）以及系统评价和荟萃分析。123篇文章进行了筛选，其中105人被评估为合格，最后，在PRISMA声明之后，有9个被列入定性综合。
■目前的证据建议，具有适度的治疗益处，在性欲减退（HSDD）的绝经后妇女中，在绝经前生理范围内使用全身性经皮睾酮，以前的低欲望功能障碍实体，主要与可改变的因素或合并症（如人际关系或心理健康问题）无关。现有证据是基于对其设计具有异质性的研究(不同的睾酮剂量，管理路线,睾酮联合使用和单独使用，性测量工具)。没有数据显示严重的短期不良反应,尽管缺乏长期安全性数据。
■尽管睾丸激素是一种有价值的工具，HSDD/FSIAD的药理学领域缺乏治疗策略。神经影像学研究可以提供有关性欲底物的有价值的信息，并建议已批准的药物对具有良好安全性的女性的潜在应用。在绝经后妇女中使用经过验证的HSDD仪器，考虑到痛苦的程度，必须能够对评估的治疗方法得出可靠的结论。
■本综述的目的是总结目前在绝经后妇女中使用睾酮治疗FSIAD的现有证据。
■对该主题进行了叙述性审查。仅考虑随机对照试验（RCTs）以及系统评价和荟萃分析。123篇文章进行了筛选，其中105人被评估为合格，最后，在PRISMA声明之后，有9个被列入定性综合。
■目前的证据建议，具有适度的治疗益处，在性欲减退（HSDD）的绝经后妇女中，在绝经前生理范围内使用全身性经皮睾酮，以前的低欲望功能障碍实体，主要与可改变的因素或合并症（如人际关系或心理健康问题）无关。现有证据是基于对其设计具有异质性的研究(不同的睾酮剂量，管理路线,睾酮联合使用和单独使用，性测量工具)。没有数据显示严重的短期不良反应,尽管缺乏长期安全性数据。
■尽管睾丸激素是一种有价值的工具，HSDD/FSIAD的药理学领域缺乏治疗策略。神经影像学研究可以提供有关性欲底物的有价值的信息，并建议已批准的药物对具有良好安全性的女性的潜在应用。在绝经后妇女中使用经过验证的HSDD仪器，考虑到痛苦的程度，必须能够对评估的治疗方法得出可靠的结论。
